ArticleThe patient2026

Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.

Kristina Boye et al.PubMed ↗Publisher ↗

No numbers read from the abstract.